The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.00
Bid: 44.60
Ask: 47.00
Change: 0.00 (0.00%)
Spread: 2.40 (5.381%)
Open: 47.00
High: 47.00
Low: 47.00
Prev. Close: 47.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

13 Jan 2021 07:00

RNS Number : 4664L
Benchmark Holdings PLC
13 January 2021
 

13 January 2021

Benchmark Holdings plc

("Benchmark" or "the Company")

Payment of contingent consideration following achievement of milestones

 

Issue of Equity

 

Benchmark (AIM: BMK), the aquaculture health, nutrition and genetics business, announces that further to the acquisition of aquaculture breeding programmes centred on shrimp from Centro de Investigación de la Acuicultura de Colombia Ceniacua on 11 August 2016, $450,000 of contingent consideration is payable following the satisfaction of specified operational milestones (the "Contingent Consideration").

At the Company's discretion, the Contingent Consideration is payable in ordinary shares in the Company using an agreed formula. The Company has therefore issued 536,272 Ordinary Shares of 0.1p each in the capital of the Company (the "New Ordinary Shares").

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading will commence at 8:00am on 18 January 2021. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 668,927,771. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Trond Williksen, CEO, commented:

 

"The payment of the contingent consideration is a reflection of the success of our shrimp genetics operations since the acquisition was made. Through a team of leading geneticists, we successfully expanded our genetics business into shrimp and developed a Specified Pathogen Resistant SPR shrimp which will be rolled out in Asia in the coming year.

 

"Specialist genetics are a significant driver of sustainable production. The introduction of SPR shrimp will help improve sustainability in shrimp production and is an important growth vector for Benchmark, as we remain focused on becoming a profitable, cash generative Group."

 

 Enquiries

For further information, please contact:

 

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

 

Septima Maguire, CFO

 

Ivonne Cantu, Investor Relations

 

 

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

 

 

 

MHP Communications

Tel: 020 3128 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver, Charlie Protheroe

benchmark@mhpc.com

 

 

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFEFUEEFSEFF
Date   Source Headline
5th Aug 20167:00 amRNSPlacing of 47.3 million new ordinary shares
29th Jul 20167:00 amRNSDirectorate Change
19th Jul 20167:00 amRNSNew Seabass Vaccine Commences Field Trials
12th Jul 20167:00 amRNSBreeding & Genetics Contract Win
28th Jun 20167:00 amRNSHalf-year Report
3rd Jun 20167:00 amRNSChange of Adviser
27th May 20167:00 amRNSChange of Auditor
26th May 20167:00 amRNSTrading Update and Notice of Results
22nd Apr 201610:45 amRNSHolding(s) in Company
18th Apr 20169:40 amRNSIssue of Equity
22nd Mar 20169:07 amRNSBlocklisting Interim Review
10th Mar 201610:13 amRNSResult of AGM
5th Feb 20162:51 pmRNSDirector Dealings
2nd Feb 20167:00 amRNSFinal Results
7th Jan 201611:02 amRNSHolding(s) in Company
5th Jan 201612:08 pmRNSHolding(s) in Company
4th Jan 20163:04 pmRNSHolding(s) in Company
4th Jan 20163:00 pmRNSHolding(s) in Company
4th Jan 201611:18 amRNSHolding(s) in Company
4th Jan 201610:47 amRNSHolding(s) in Company
4th Jan 201610:43 amRNSHolding(s) in Company
4th Jan 201610:40 amRNSHolding(s) in Company
4th Jan 20169:26 amRNSHolding(s) in Company
4th Jan 20169:19 amRNSHolding(s) in Company
31st Dec 20157:00 amRNSFurther admission of shares
29th Dec 201511:43 amRNSResult of General Meeting
14th Dec 201511:00 amRNSSchedule 1 - Benchmark Holdings plc
14th Dec 20157:30 amRNSRestoration - Benchmark Holdings plc
14th Dec 20157:00 amRNSPlacing and Acquisition
9th Nov 20157:00 amRNSCanine Vaccine Licensing Deal Secured
6th Nov 201511:28 amRNSResponse to Lumpfish VHS
8th Oct 20152:43 pmRNSFurther re. potential acquisition
8th Oct 201512:15 pmRNSPotential acquisition and suspension of shares
8th Oct 201512:15 pmRNSSuspension - Benchmark Holdings Plc
30th Sep 20157:00 amRNSSalmoBreed breakthrough
30th Sep 20157:00 amRNSTotal Voting Rights
16th Sep 20157:00 amRNSBlock Admission Application
27th Jul 20157:00 amRNSAcquisition
13th Jul 20153:40 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHalf Yearly Report
6th May 20155:46 pmRNSHolding(s) in Company
30th Apr 201512:44 pmRNSHolding(s) in Company
29th Apr 20157:00 amRNSTrading Statement
23rd Apr 201512:34 pmRNSHolding(s) in Company
17th Mar 201512:25 pmRNSHolding(s) in Company
10th Mar 20151:13 pmRNSDirector Share Options
5th Mar 201510:43 amRNSResult of AGM
26th Feb 20152:39 pmRNSHolding(s) in Company
16th Feb 20151:51 pmRNSHolding(s) in Company
3rd Feb 201512:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.